|Bid||88.56 x 900|
|Ask||88.71 x 800|
|Day's range||85.87 - 90.25|
|52-week range||33.57 - 134.00|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||124.86|
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 19.72% and -100.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Top-line Phase 2 a Data from Etokimab in Eosinophilic Asthma Expected in Third Quarter of 2018 Etokimab Clinical Development Program Expanded to Include Chronic Rhinosinusitis with Nasal Polyps Commercial ...
SAN DIEGO, Aug. 06, 2018-- AnaptysBio, Inc., a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced ...
NEW YORK, July 25, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Martin ...
AnaptysBio dipped Tuesday despite trial results showing its peanut-allergy drug improved symptoms in nearly half of adult patients tested.